All In Biotech

NDA 022512 · Boehringer Ingelheim

Pradaxa

Dabigatran Etexilate Mesylate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Oct 19, 2010

Approved uses

4

Original approval plus efficacy supplements

Registered trials

250

45 Phase 3, 26 recruiting

FAERS reports

73,751

56,526 serious, 10,958 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including PRADAXA, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy ( 2.6 , 2.7 , 2.8 , 5.1 ). (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with PRADAXA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may...

What it is approved for

From the label in effect Jun 25, 2025.

PRADAXA Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients PRADAXA Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery PRADAXA Capsules is...

Mechanism: Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • PRADAXA · DABIGATRAN ETEXILATE MESYLATE EQ 110MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • PRADAXA · DABIGATRAN ETEXILATE MESYLATE EQ 75MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • PRADAXA · DABIGATRAN ETEXILATE MESYLATE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dabigatran Etexilate" as an intervention, any sponsor and status, largest first.

All 250 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gastrointestinal haemorrhage7,976
  • cerebrovascular accident3,968
  • fall3,079
  • haemorrhage3,048
  • anaemia2,661
  • ischaemic stroke2,199
  • death2,144
  • dyspnoea2,084
  • rectal haemorrhage2,010
  • dizziness1,985
  • atrial fibrillation1,801
  • diarrhoea1,704

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20075
20083
20094
2010410
201111,548
20129,133
20137,940
20147,200
20154,610
20165,590
20176,566
20185,564
20193,960
20202,994
20212,513
20222,217
20231,166
2024976
2025832
2026520

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pradaxa (Dabigatran Etexilate Mesylate)

2024 spending

$123M

Beneficiaries

139,514

481,836 claims

Per beneficiary

$883

$1.82 per unit

View as table
YearSpending
2020$599,577,175
2021$571,018,502
2022$469,904,882
2023$176,220,137
2024$123,182,256

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 134 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.